Cambridge Nutritional Sciences Plc
(the "Company" or "CNSL")
Directorate Change
CNSL (AIM:CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, is pleased to announce that it has appointed James Cooper to the Board as Chief Operating Officer ("COO") and Executive Director with immediate effect.
James graduated from the University of Cambridge in 2014 and, prior to joining CNSL as Operations Director in January this year, has spent the previous 10 years at Chartwell Consulting Limited, a global operations consultancy firm, working most recently on assignments in the medical and pharmaceuticals sectors.
Carolyn Rand, Chair, said: "As a Board, we are committed to strengthening both our operational performance and our organisation to deliver profitable growth in an exciting market. We have created a new Board level position of COO as part of this ongoing process and are delighted to be promoting James into the role, who I am certain will play a key part in our future success".
Jag Grewal, Chief Executive Officer, said: "In his short time with us, James has already made a very significant contribution to CNSL's manufacturing operations, and I am delighted that he has agreed to step up to the role of COO where I look forward to working closely with him to drive our business forwards."
Contacts:
| Cambridge Nutritional Sciences Plc | ||
| Jag Grewal, Chief Executive Officer | investors@cnsplc.com | |
| | | |
| Cavendish Capital Markets Limited | Tel: 020 7220 0500 | |
| Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance) | | |
| Nigel Birks / Harriet Ward (ECM) | | |
| | | |
About Cambridge Nutritional Sciences Plc
Cambridge Nutritional Sciences Plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.
The following disclosures are made in accordance with Schedule 2(g) of the AIM Rules for Companies:
James Samuel Cooper, aged 32, holds 265,480 ordinary shares of 4 pence each in the capital of the Company representing 0.11 per cent. of the Company's issued share capital. James holds no options in the Company. James has no previous directorships or partnerships.
Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
